The Human Cancer Models Initiative aims to create about 1,000 cancer cell lines that scientists can use to study tumor progression, drug resistance, and more.
The researchers will use Sapientia to analyze samples from 1,000 fetuses as part of efforts to develop an exome-based assay for non-invasive prenatal testing.
The supercomputer was used to identify genomic variants in some 300 deeply sequenced human samples for use in a planned bead-array-based genotyping chip.
The study expands on the known genetic subtypes, shows that they are correlated with clinical outcome, and paves the way for better subtype-driven patient management.
Sanger Institute researchers analyzed the genomes and mutational signatures of 560 breast cancer tumors, identifying new ways to classify the disease.
The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio.
By sequencing the genomes of more than 300 Shigella dysenteriae isolates, researchers identified lineages involved in worldwide outbreaks prior to WWI.
Researchers used the computational method to identify T cell clonotypes in a mouse Salmonella infection model.
Investigators looked at potential health impacts for the rare, homozygous loss-of-function mutations they detected in 3,200 British-Pakistani individuals.
Sequences from Chlamydia trachomatis strains in northern Australia suggest trachoma infections in the eye may be caused by small changes to urogenital strains.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.